Abstract
870P - A phase IIa study of radium-223 dichloride (Ra-223) alone or in combination with abiraterone acetate or enzalutamide in metastatic castration-resistant prostate cancer (mCRPC)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have